Key facts
- Hummingbird (Surgical Devices)’s last known valuation is $65.0M (Feb 2023).
- It has raised $23.5M; the latest was Later Stage VC ($2.0M) in Jan 2025.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Lateral Capital Management, Heuristic Capital Partners, Omphalos Venture Partners, Atlas Capital Partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Hummingbird (Surgical Devices)
- ·The full record, as it builds
Funding rounds
No funding rounds for Hummingbird (Surgical Devices) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hummingbird (Surgical Devices)
Developer of a tympanostomy tube system designed to offer conscious sedation options for ear tube placement. The company's system offers an alternative to general anesthesia and minimizes surgical trauma during ear tube placement, enabling physicians to use moderate sedation for routine ear tube procedures.
- Sector
- Healthcare
- HQ
- Golden Valley, MN, United States
- Founded
- 2011
- Employees
- 10
- Website
- hummingbirdeartubes.com/
- Ownership
- Privately Held (backing)
Hummingbird (Surgical Devices) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hummingbird (Surgical Devices) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hummingbird (Surgical Devices) in its N-PORT filings yet. We sweep new filings monthly.